# Trends in Inhibitors, Structural Modifications, and Structure–Function Relationships of Phosphodiesterase 4: A Review

## TL;DR

This review discusses the structure and function of PDE4, a key enzyme in inflammation, and explores how inhibitors and natural compounds can be optimized for better therapeutic outcomes.

## Contribution

The paper highlights the potential of natural compounds and structural insights for developing isoform-selective PDE4 inhibitors with improved safety profiles.

## Key findings

- Current PDE4 inhibitors like roflumilast have dose-dependent adverse effects due to lack of isoform selectivity.
- Natural compounds such as curcumin and α-mangostin offer structural diversity and lower toxicity for PDE4 inhibition.
- Combining structural studies with natural compound optimization can lead to safer, more selective PDE4 inhibitors.

## Abstract

Phosphodiesterase 4 (PDE4) is a key enzyme responsible for the hydrolysis of cyclic adenosine monophosphate (cAMP), thereby regulating essential signaling pathways involved in inflammation and immune modulation. Structural studies have demonstrated a high degree of conservation within the catalytic domains of PDE4 isoforms, accompanied by subtle conformational variations that underlie their selectivity and tissue-specific distribution. Elucidating these structural features has been instrumental in guiding the rational design of PDE4 inhibitors. Although synthetic PDE4 inhibitors such as roflumilast and apremilast exhibit significant therapeutic efficacy, their clinical application is often limited by dose-dependent adverse effects. These effects primarily arise from insufficient isoform selectivity, as current inhibitors tend to target multiple PDE4 subtypes indiscriminately, resulting in off-target pharmacological actions and reduced tolerability. In contrast, natural products—including flavonoids, terpenoids, and related polyphenolic compounds such as curcumin, α-mangostin, and their derivatives—have emerged as promising molecular scaffolds. Their lower toxicity, favorable biocompatibility, and structural diversity enable fine-tuning of potency and selectivity through rational modification. Integrating structural insights derived from crystallographic and computational studies with the optimization of natural compounds offers a sustainable and effective strategy for the development of safer, isoform-selective PDE4-targeted therapies.